实用肝脏病杂志 ›› 2018, Vol. 21 ›› Issue (2): 170-176.doi: 10.3969/j.issn.1672-5069.2018.02.006
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会
收稿日期:2018-01-02
出版日期:2018-03-10
发布日期:2018-03-19
通讯作者:
厉有名,310003 杭州市,浙江大学医学院附属第一医院消化内科,E-mail: zlym@zju.edu.cn;范建高,200092 上海交通大学医学院附属新华医院消化内科,E-mail:fattyliver2004@126.com
National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association
Received:2018-01-02
Online:2018-03-10
Published:2018-03-19
Contact:
Li Youming,E-mail:中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 酒精性肝病防治指南（2018年更新版）[J]. 实用肝脏病杂志, 2018, 21(2): 170-176.
National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:a 2018 update[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 170-176.
| [1] 酒依赖与肝病问题调查协作组.中国9个城市4种职业人群酒依赖协作研究(一)(二)[J]. 中国心理卫生杂志,1992,6:112. [2] 陈士林,孟晓丹,王炳元,等. 辽宁省部分城市酒精性肝病流行现状调查[J]. 实用肝脏病杂志,2010,13(6):428-430,435. DOI:10.3969/j.issn.1672-5069.2010.06.010. [3] Wang H,Ma L,Yin Q,et al.Prevalence of alcoholic liver disease and its association with socioeconomic status in north-eastern China[J]. Alcohol Clin Exp Res,2014,38(4):1035-1041. DOI:10.1111/acer.12321. [4] 黄顺玲,戴水奇,张雪红,等. 湖南省酒精性肝病流行病学调查概况[J]. 中国医师杂志,2005,7(3):426-427. DOI:10.3760/cma.j.issn.1008-1372.2005.03.080. [5] 鲁晓岚,陶明,罗金燕,等. 饮酒与肝病流行病学调查[J].中华肝脏病杂志,2002,10(6):467-468. DOI:10.3760/j.issn:1007-3418.2002.06.029. [6] 厉有名,陈卫星,虞朝辉,等. 浙江省酒精性肝病流行病学调查概况[J]. 中华肝脏病杂志,2003,11(11):647-649. DOI:10.3760/j.issn:1007-3418.2003.11.002. [7] Zhou YJ,Li YY,Nie YQ,et al.Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol,2007,13(47):6419-6424. [8] 姚锦慧,赵秋冬,熊鹏芬,等. 云南元江少数民族酒精性肝病流行病学调查[J].胃肠病学和肝病学杂志,2011,20(12):1137-1139. DOI:10.3969/j.issn.1006-5709.2011.12.021. [9] 全国酒精性肝病调查协作组.全国酒精性肝病的多中心调查分析[J].中华消化杂志,2007,27(4):231-234.DOI:10.3760/j.issn:0254-1432.2007.04.005. [10] 刘阳,迟宝荣.酒精性肝硬化237例临床分析[J].吉林医学,2004,25(4):40-42.DOI: 10.3969/j.issn.1004-0412.2004.02.016. [11] 王辉,王江滨. 肝炎病毒感染与酒精性肝硬化关系的研究(附182例酒精性肝病临床病例报告)[J].白求恩医科大学学报,1998,24(6):652-653. [12] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China[J]. Hepatology,2014,60(6):2099-2108. DOI:10.1002/hep.27406. [13] Rehm J,Taylor B,Mohapatra S,et al.Alcohol as a risk factor for liver cirrhosis:a systematic review and meta-analysis[J]. Drug Alcohol Rev,2010,29(4):437-445. DOI:10.1111/j.1465-3362.2009.00153.x. [14] Shen Z,Li YM,Yu CH,et al.Risk factors for alcohol-related liver injury in the island population of China:a population-based case-control study[J].World J Gastroenterol,2008,14(14):2255-2261. [15] Becker U,Deis A,Sorensen TI,et al.Prediction of risk of liver disease by alcohol intake,sex,and age:a prospective population study[J].Hepatology,1996,23(5):1025-1029. DOI: 10.1002/hep.510230513. [16] Corrao G,Bagnardi V,Zambon A,et al.A meta-analysis of alcohol consumption and the risk of 15 diseases[J]. Prev Med,2004,38(5):613-619. DOI:10.1016/j.ypmed.2003.11.027. [17] Kamper-Jørgensen M,Grønbaek M,Tolstrup J,et al.Alcohol and cirrhosis:dose-response or threshold effect[J]. J Hepatol,2004,41(1):25-30. DOI:10.1016/j.jhep.2004.03.002. [18] Becker U,GrønbaekM,Johansen D,et al. Lower risk foralcohol-induced cirrhosis in wine drinkers[J]. Hepatology,2002,35(4):868-875. DOI:10.1053/jhep.2002.32101. [19] Jiang H,Livingston M,Room R,et al.Alcohol consumption and liver disease in Australia:a time series analysis of the period 1935-2006[J]. Alcohol Alcohol,2014,49(3):363-368. DOI: 10.1093/alcalc/agt143. [20] Lu XL,Luo JY,Tao M,et al.Risk factors for alcoholic liver disease in China[J]. World J Gastroenterol,2004,10(16):2423-2426. [21] Hatton J,Burton A,Nash H,et al.Drinking patterns,dependency and life-time drinking history in alcohol-related liver disease[J].Addiction,2009,104(4):587-592. DOI: 10.1111/j.1360-0443.2008.02493.x. [22] Sato N,Lindros KO,Baraona E,et al.Sex difference in alcohol-related organ injury[J]. Alcohol Clin Exp Res,2001,25(5 Suppl ISBRA):40S-45S. [23] Eagon PK.Alcoholic liver injury:influence of gender and hormones[J]. World J Gastroenterol,2010,16(11):1377-1384. [24] Baraona E,Abittan CS,Dohmen K,et al.Gender differences in pharmacokinetics of alcohol[J]. Alcohol Clin Exp Res,2001,25(4):502-507. [25] Wickramasinghe SN,Corridan B,Izaguirre J,et al.Ethnic differences in the biological consequences of alcohol abuse:a comparison between south Asian and European males[J]. Alcohol Alcohol,1995,30(5):675-680. [26] Borràs E,Coutelle C,Rosell A,et al.Genetic polymorphism of alcohol dehydrogenase in europeans:the ADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1[J]. Hepatology,2000,31(4):984-989. [27] Yu C,Li Y,Chen W,et al.Genotype of ethanol metabolizing enzyme genes by oligonucleotide microarray in alcoholic liver disease in Chinese people[J].Chin Med J (Engl),2002,115(7):1085-1087. [28] Mendenhall C,Roselle GA,Gartside P,et al.Relationship of protein calorie malnutrition to alcoholic liver disease:a reexamination of data from two Veterans Administration Cooperative Studies[J].Alcohol Clin Exp Res,1995,19(3):635-641. [29] Leevy CM,Moroianu SA.Nutritional aspects of alcoholic liver disease[J].Clin Liver Dis,2005,9(1):67-81. DOI:10.1016/j.cld.2004.11.003. [30] Mezey E.Dietary fat and alcoholic liver disease[J]. Hepatology,1998,28(4):901-905. DOI: 10.1002/hep.510280401. [31] Williams R.Global challenges in liver disease[J]. Hepatology,2006,44(3):521-526. DOI:10.1002/hep.21347. [32] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J]. 中华肝脏病杂志,2006,14(3):164-166. DOI:10.3760/j.issn:1007-3418.2006.03.002. [33] Bush K,Kivlahan DR,Mcdonell MB,et al.The AUDIT alcohol consumption questions(AUDIT-C):an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test[J].Arch Intern Med,1998,158(16):1789-1795. [34] Soderstrom CA,Smith GS,Kufera JA,et al.The accuracy of the CAGE,the Brief Michigan Alcoholism Screening Test,and the Alcohol Use Disorders Identification Test in screening trauma center patients for alcoholism[J].J Trauma,1997,43(6):962-969. [35] Chen CH,Huang MH,Yang JC,et al.Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan[J]. J Gastroenterol Hepatol,2007,22(9):1482-1489.DOI:10.1111/j.1440-1746.2006.04615.x. [36] Conigrave KM,Degenhardt LJ,Whitfield JB,et al.CDT,GGT, and AST as markers of alcohol use:the WHO/ISBRA collaborative project[J]. Alcohol Clin Exp Res,2002,26(3):332-339. [37] Yersin B,Nicolet JF,Dercrey H,et al.Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin,gamma-glutamyltransferase,and mean corpuscular volume[J]. Arch Intern Med,1995,155(17):1907-1911. [38] Majhi S,Baral N,Lamsal M,et al.De Ritis ratio as diagnostic marker of alcoholic liver disease[J]. Nepal Med Coll J,2006,8(1):40-42. [39] Nyblom H,Berggren U,Balldin J,et al.High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking[J]. Alcohol Alcohol,2004,39(4):336-339. DOI: 10.1093/alcalc/agh074. [40] Bardou-Jacquet E,Legros L,Soro D,et al.Effect of alcohol consumption on liver stiffness measured by transient elastography[J]. World J Gastroenterol,2013,19(4):516-522. DOI:10.3748/wjg.v19.i4.516. [41] Bensamoun SF,Leclerc GE,Debernard L,et al.C utoff values for alcoholic liver fibrosis using magnetic resonance elastography technique[J].Alcohol Clin Exp Res,2013,37(5):811-817. DOI: 10.1111/acer.12025. [42] d'Assignies G,Ruel M,Khiat A,et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods[J].Eur Radiol,2009,19(8):2033-2040. DOI: 10.1007/s00330-009-1351-4. [43] Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease[J]. Invest Radiol,2000,35(5):319-324. [44] Ataseven H,Yildrim MH,Yalniz M,et al. Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis [J]. J Hepatol,2003,38 Suppl 2:A4177. [45] Farrell GC,George J,Pauline de la M,et al. Fatty liver disease: NASH and related disorders. Oxford:Blsckwell Publishing,2005, 159-207. [46] Mancini M,Prinster A,Annuzzi G,et al.Sonographic hepatic-renal ratio as indicator of hepatic steatosis:comparison with (1)H magnetic resonance spectroscopy[J].Metabolism,2009,58(12):1724-1730.DOI:10.1016/j.metabol.2009.05.032. [47] Nahon P,Kettaneh A,Tengher-Barna I,et al.Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease[J]. J Hepatol,2008,49(6):1062-1068. DOI:10.1016/j.jhep.2008.08.011. [48] Sanyal AJ,American Gastroenterological Association.AGA technical review on nonalcoholic fatty liver disease[J].Gastroenterology,2002,123(5):1705-1725. [49] 沈峰,范建高.瞬时弹性成像技术在脂肪性肝病中的应用现状[J].中华肝脏病杂志,2014,22(9):643-646. DOI:10.3760/cma.j.issn.1007-3418.2014.09.002. [50] 沈峰,郑瑞丹,宓余强,等.受控衰减参数诊断脂肪肝的临界值初探:一项多中心临床研究[J].中华肝脏病杂志,2014,22(12): 926-931.DOI:10.3760/cma.j.issn.1007-3418.2014.12.010. [51] 瞬时弹性成像技术(TE)临床应用共识专家委员会. 瞬时弹性成像技术(TE)临床应用专家共识(2015年)[J].中国肝脏病杂志(电子版),2015,7(2):12-18. DOI:10.3969/j.issn.1674-7380.2015.02.002. [52] Singh S,Fujii LL,Murad MH,et al.Liver stiffness is associated with risk of decompensation,liver cancer,and death in patients with chronic liver diseases:a systematic review and meta-analysis[J].Clin Gastroenterol Hepatol,2013,11(12):1573-1584. DOI: 10.1016/j.cgh.2013.07.034. [53] European Association for Study of Liver,Asociacion Latinoamericana para el Estudio del Higado.EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol,2015,63(1):237-264. DOI:10.1016/j.jhep.2015.04.006. [54] Castera L.Hepatitis B:are non-invasive markers of liver fibrosis reliable[J]. Liver Int,2014,34 Suppl 1:91-96. DOI: 10.1111/liv.12393. [55] Huwart L,Sempoux C,Vicaut E,et al.Magnetic resonance elastography for the noninvasive staging of liver fibrosis[J].Gastroenterology,2008,135(1):32-40. DOI:10.1053/j.gastro.2008.03.076. [56] Carithers RL Jr,Herlong HF,Diehl AM,et al.Methylprednisolone therapy in patients with severe alcoholic hepatitis.A randomized multicenter trial[J].Ann Intern Med,1989,110(9):685-690. [57] Dominguez M,Rincón D,Abraldes JG,et al.A new scoring system for prognostic stratification of patients with alcoholic hepatitis[J]. Am J Gastroenterol,2008,103(11):2747-2756. DOI:10.1111/j.1572-0241.2008.02104.x. [58] Forrest EH,Evans CD,Stewart S,et al.Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score[J]. Gut,2005,54(8):1174-1179. DOI: 10.1136/gut.2004.050781. [59] Louvet A,Naveau S,Abdelnour M,et al.The Lille model:a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids[J]. Hepatology,2007,45(6):1348-1354. DOI:10.1002/hep.21607. [60] Papastergiou V,Tsochatzis EA,Pieri G,et al.Nine scoring models for short-term mortality in alcoholic hepatitis:cross-validation in a biopsy-proven cohort[J]. Aliment Pharmacol Ther,2014,39(7):721-732. DOI:10.1111/apt.12654. [61] Said A,Williams J,Holden J,et al.Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease[J]. J Hepatol,2004,40(6):897-903. DOI:10.1016/j.jhep.2004.02.010. [62] Srikureja W,Kyulo NL,Runyon BA,et al.MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis[J]. J Hepatol,2005,42(5):700-706. DOI:10.1016/j.jhep.2004.12.022. [63] Barve A,Khan R,Marsano L,et al.Treatment of alcoholic liver disease[J]. Ann Hepatol,2008,7(1):5-15. [64] European Association for the Study Of Liver. EASL clinical practical guidelines:management of alcoholic liver disease[J].J Hepatol,2012,57(2):399-420. DOI:10.1016/j.jhep.2012.04.004. [65] Tilg H,Day CP.Management strategies in alcoholic liver disease[J]. Nat Clin Pract Gastroenterol Hepatol,2007,4(1):24-34. DOI: 10.1038/ncpgasthep0683. [66] O'shea RS,Dasarathy S,Mccullough AJ,et al. Alcoholic liver disease[J]. Hepatology,2010,51(1):307-328. DOI:10.1002/hep.23258. [67] DiCecco SR,Francisco-Ziller N.Nutrition in alcoholic liver dise-ase[J]. Nutr Clin Pract,2006,21(3):245-254. DOI:10.1177/0115426506021003245. [68] McClain CJ,Barve SS,Barve A,et al.Alcoholic liver disease and malnutrition[J]. Alcohol Clin Exp Res,2011,35(5):815-820.DOI:10.1111/j.1530-0277.2010.01405.x. [69] Stickel F,Hoehn B,Schuppan D,et al.Review article:Nutritional therapy in alcoholic liver disease[J].Aliment Pharmacol Ther,2003,18(4):357-373. [70] Mathurin P,O'grady J,Carithers RL,et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis:meta-analysis of individual patient data[J]. Gut,2011,60(2):255-260. DOI: 10.1136/gut.2010.224097. [71] Thursz MR,Richardson P,Allison M,et al.Prednisolone or pentoxifylline for alcoholic hepatitis[J]. N Engl J Med,2015,372(17):1619-1628. DOI:10.1056/NEJMoa1412278. [72] Guerrini I,Gentili C,Nelli G,et al.A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence[J]. Subst Abuse Treat Prev Policy,2006,1:35. DOI: 10.1186/1747-597X-1-35. [73] Leggio L,Kenna GA,Ferrulli A,et al.Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease[J]. Hum Psychopharmacol,2011,26(8):554-559. DOI:10.1002/hup.1244. [74] Shpilenya LS,Muzychenko AP,Gasbarrini G,et al.Metadoxine in acute alcohol intoxication:a double-blind,randomized,placebocontrolled study[J]. Alcohol Clin Exp Res,2002,26(3):340-346. [75] Higuera-de la Tijera F,Servín-Caamano AI,Serralde-Zú?iga AE,et al. Metadoxine improves the three-and six-month survival rates in patients with severe alcoholic hepatitis[J]. World J Gastroenterol,2015,21(16):4975-4985. DOI: 10.3748/wjg.v21.i16.4975. [76] 茅益民,曾民德,陆伦根,等. 美他多辛治疗酒精性肝病的多中心、随机、双盲、安慰剂平行对照的临床研究[J]. 中华肝脏病杂志,2009,17(3):213-216. DOI:10.3760/cma.j.issn.1007-3418.2009.03.013. [77] Mato JM,Cámara J,Fernández de Paz J,et al.S-adenosylmethionine in alcoholic liver cirrhosis:a randomized,placebo-controlled,double-blind,multicenter clinical trial[J]. J Hepatol 1999,30(6):1081-1089. [78] 白冰,何清,唐尉,等. S-腺苷蛋氨酸治疗酒精性肝病的系统评价[J]. 中国肝脏病杂志(电子版),2012, 4(2):1-9. DOI:10.3969/j.issn.1674-7380.2012.02.001. [79] 邢全台,袁孟彪,高新民.思美泰治疗酒精性肝病疗效观察[J].胃肠病学和肝病学杂志,2002,11(3):239-240,242. DOI:10.3969/j.issn.1006-5709.2002.03.016. [80] Medina J,Moreno-Otero R.Pathophysiological basis for antioxidant therapy in chronic liver disease[J]. Drugs,2005,65(17):2445-2461. [81] 胡国平,刘凯,赵连三. 多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. DOI:10.3969/j.issn.1008-1704.2005.01.003. [82] 方丽华,张虹.还原型谷胱甘肽联合利加隆治疗酒精性肝炎疗效观察[J]. 肝脏,2004,9(3):181-182. DOI:10.3969/j.issn.1008-1704.2004.03.013. [83] 李丽军,李卫. 还原型谷胱甘肽治疗酒精性肝病35例临床观察[J]. 实用肝脏病杂志,2007,10(5):329-330. DOI:10.3969/j.issn.1672-5069.2007.05.018. [84] 张全海,郭树华,胡大荣,等. 国产还原型谷胱甘肽治疗酒精性肝病疗效观察[J]. 中华肝脏病杂志,2000,8(4):239-240. DOI:10.3760/j.issn:1007-3418.2000.04.015. [85] 马安林,郭新珍,刘霞,等. 双环醇与多烯磷脂酰胆碱治疗酒精性肝病的疗效比较[J]. 中华肝脏病杂志,2011,19(6):471-472. DOI:10.3760/cma.j.issn.1007-3418.2011.06.020. [86] 马安林,刘淑娥,刘霞,等. 双环醇与多烯磷脂酰胆碱治疗酒精性脂肪肝的临床病理比较[J].临床肝胆病杂志,2006,22(4):272-275. DOI:10.3969/j.issn.1001-5256.2006.04.014. [87] Mathurin P,Moreno C,Samuel D,et al.Early liver transplantation for severe alcoholic hepatitis[J]. N Engl J Med,2011,365(19):1790-1800.DOI:10.1056/NEJMoa1105703. [88] Murray KF,Carithers RL Jr,AASLD. AASLD practice guidelines:Evaluation of the patient for liver transplantation[J]. Hepatology,2005,41(6):1407-1432. DOI:10.1002/hep.20704. |
| [1] | 鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769. |
| [2] | 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792. |
| [3] | . 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803. |
| [4] | 任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807. |
| [5] | 高磊, 曹蕾, 王瑞芳, 冯丹丹, 薛娟. 人脐带间充质干细胞移植对酒精性肝损伤大鼠的保护作用*[J]. 实用肝脏病杂志, 2019, 22(6): 812-815. |
| [6] | 石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823. |
| [7] | 吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835. |
| [8] | 李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851. |
| [9] | 邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855. |
| [10] | 段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867. |
| [11] | 朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875. |
| [12] | 陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883. |
| [13] | 马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895. |
| [14] | 曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899. |
| [15] | 曾艳妮, 张灿, 毕俊英, 刘良进, 孟俊, 秦涛. MRI长时间延迟增强扫描诊断肝脏孤立性坏死性结节价值研究*[J]. 实用肝脏病杂志, 2019, 22(6): 900-903. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
